What is the appropriate management plan for a patient with chronic stable angina?

Management of Chronic Stable Angina

All patients with chronic stable angina should receive aspirin, a beta-blocker, and a high-intensity statin as foundational therapy, with sublingual nitroglycerin for acute symptom relief. 1

Pharmacotherapy to Prevent MI and Death

Mandatory Medications for All Patients

• Aspirin 75-325 mg daily reduces cardiovascular events and should be prescribed unless absolutely contraindicated 1, 2
• Clopidogrel 75 mg daily is the only acceptable alternative when aspirin is absolutely contraindicated 1
• High-intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) reduces adverse ischemic events regardless of baseline LDL cholesterol 1, 2
• ACE inhibitor should be added for all patients, with particularly strong evidence in those with diabetes, hypertension, heart failure, left ventricular dysfunction, or prior MI 1, 2

Beta-Blocker Therapy

• Beta-blockers are first-line for symptom control and provide mortality benefit in patients with prior MI 1, 2
• Titrate to maximum tolerated dose before adding additional antianginal agents 3, 2
• Never abruptly discontinue beta-blockers—taper over 4 weeks if discontinuation is necessary to prevent rebound angina 3, 2
• All beta-blockers appear equally effective for angina control 4

Pharmacotherapy for Symptom Relief

Acute Symptom Management

• Sublingual nitroglycerin 0.3-0.6 mg or sublingual isosorbide dinitrate 2.5-10 mg for immediate relief of acute angina episodes 1, 5, 2
• Relief should occur within 1-7 minutes 5
• Instruct patients to call emergency services if symptoms are unimproved or worsening 5 minutes after one dose 5
• Patients should sit when first using sublingual nitrates to avoid hypotension-related falls 5
• Can be used prophylactically before activities known to trigger angina 5, 2

Chronic Maintenance Therapy Algorithm

Step 1: Beta-blocker monotherapy (unless contraindicated)

• Titrate to maximum tolerated dose 3, 2
• Contraindications include severe asthma, symptomatic bradycardia, high-degree heart block 3

Step 2: If beta-blocker contraindicated or causes intolerable side effects

• Add long-acting calcium channel blocker (preferably dihydropyridine like amlodipine 5-10 mg daily) OR long-acting nitrate (oral isosorbide dinitrate 5-80 mg 2-3 times daily with 10-14 hour nitrate-free interval) 1, 5, 3, 2
• Long-acting calcium channel blockers are often preferable to long-acting nitrates because they provide sustained 24-hour effects without requiring a drug-free interval 1

Step 3: If beta-blocker monotherapy insufficient

• Add dihydropyridine calcium channel blocker (e.g., amlodipine) to beta-blocker 3, 2
• This combination has the strongest evidence for additive anti-anginal effects 3
• Alternatively, add long-acting nitrate with mandatory 10-14 hour nitrate-free interval 1, 5, 3

Step 4: If two-drug combination fails

• Do not routinely add a third antianginal drug—clinical trials demonstrate three drugs may provide less symptomatic protection than two optimized drugs 3
• Instead, verify medication adherence and ensure both drugs are at maximum therapeutic doses 3
• Consider switching from calcium channel blocker to long-acting nitrate (or vice versa) while maintaining beta-blocker 3
• Refer for coronary angiography and potential revascularization when symptoms remain uncontrolled after maximal therapeutic doses of two drugs 3, 2

Step 5: Ranolazine for refractory symptoms

• Ranolazine 500-1000 mg twice daily can be added to existing antianginal therapy in patients with persistent symptoms despite optimal medical therapy 6
• Reduces angina frequency and nitroglycerin use without significant effects on heart rate or blood pressure 6
• Particularly useful when added to amlodipine 10 mg daily 6

Critical Medication Pitfalls

• Never use short-acting dihydropyridine calcium antagonists (e.g., immediate-release nifedipine) without concurrent beta-blocker—they increase adverse cardiac events 1, 3, 2
• Do not prescribe dipyridamole—it can enhance exercise-induced myocardial ischemia 1, 2
• Do not use chelation therapy—no evidence of benefit 1, 2
• Avoid sildenafil or other PDE-5 inhibitors in patients taking nitrates—risk of severe hypotension 1, 3
• Maintain nitrate-free interval of 10-14 hours daily to prevent tolerance with long-acting nitrates 1, 5, 3

Risk Factor Modification

Lipid Management

• Target LDL cholesterol <130 mg/dL with statin therapy 1
• In patients with triglycerides >200 mg/dL, target non-HDL cholesterol <130 mg/dL 1

Other Modifiable Risk Factors

• Smoking cessation is mandatory 1
• Blood pressure control to <130/85 mm Hg, especially in metabolic syndrome 1
• Weight reduction for obesity (waist circumference >103 cm in men, >88 cm in women) 1
• Glycemic control in diabetes with fasting glucose monitoring 1
• Physical activity should be encouraged with appropriate symptom monitoring 1

Revascularization Considerations

• Coronary artery bypass grafting (CABG) improves survival in symptomatic patients with left main disease, three-vessel disease, or two-vessel disease including proximal left anterior descending stenosis 4
• Percutaneous coronary intervention (PCI) is an alternative for patients with normal left ventricular function and favorable anatomy 4
• Revascularization does not reduce mortality or MI risk in most stable angina patients but may be required for symptom control 4, 7
• CABG is initially more effective than medical therapy for angina relief, but results are similar after 5-10 years 4

Alternative Therapies for Refractory Angina

When symptoms persist despite optimal medical therapy and revascularization is not feasible:

• Enhanced external counterpulsation (EECP) decreases angina frequency and improves exercise tolerance, with 75-80% of patients reporting symptom improvement 1
• Spinal cord stimulation may provide analgesia but has limited long-term data 1
• Surgical transmyocardial revascularization (TMR) improves symptoms but has not demonstrated increased myocardial perfusion 1
• These techniques should only be used when medical therapy is inadequate and revascularization is not possible 1

Patient Follow-Up Protocol

Visit Frequency

• Every 4-6 months during the first year of therapy 1
• Annually thereafter if stable and patient can reliably report symptom changes 1
• More frequent visits for unreliable patients or those needing additional support 1

Essential Questions at Each Visit

1. Has physical activity level decreased since last visit? 1
2. Have anginal symptoms increased in frequency or severity? 1
3. How well is the patient tolerating therapy? 1
4. How successful has risk factor modification been? 1
5. Have new comorbid illnesses developed or worsened? 1

Physical Examination Focus

• Weight, blood pressure, and pulse at every visit 1
• Jugular venous pressure and carotid examination 1
• Pulmonary examination for rales, wheezing, or decreased breath sounds 1
• Cardiac examination for new murmurs or signs of heart failure 1

Cardiac Testing During Follow-Up

• No routine periodic testing without clinical change 1
• Repeat ECG when medications affecting cardiac conduction are initiated or changed, or when anginal pattern changes 1
• Chest radiography for new or worsening heart failure 1
• Echocardiography for new heart failure, suspected MI, or new valvular disease 1
• Treadmill exercise test for patients with significant clinical status change who have not undergone previous revascularization 1